Upon tumor manifestation, we treated mice with NVP-2 (2.5 or 5 mg/kg, once per day, 5 d per week) or vehicle followed by an assessment of CDK9 inhibition (pSer2), tumor response (ultrasound, liver enzymes, and histology), and overall survival. Here, CDK9 is linked to neoplasm.